You have read all your free articles, to continue reading subscribe to read the rest of this content.
Swedish Orphan Biovitrum AB has announced the commercial launch of Elocta (efmoroctocog alfa) in first countries in Europe. Elocta is a recombinant human factor VIII Fc fusion protein with an extended half-life, and is the first haemophilia A treatment in the EU to offer prolonged protection agaiAlready a subscriber Login…
Three members of the company's Board, Solveig Hellebust, Jean Pierre Bizzari and Thomas Ramdahl, has decided to step down from the Board with immediate effect. Following the decisions to discontinue the PARADIGME study for Betalutin, restructure the company and appoint Carnegie Investment Bank toAlready a subscriber Login You have read…
The supplemental Biologics License Application (sBLA) for Ultomiris (ravulizumab-cwvz) in adults with generalised myasthenia gravis (gMG) has been accepted for Priority Review by the US Food and Drug Administration (FDA). The FDA set a Prescription Drug User Fee Act date during the second quartAlready a subscriber Login You have read all your…
Medivir has announced that the Board of Directors has tasked the company management with reviewing the possibility of dividing the company’s operations into two independent companies and achieving a separate listing for the commercial pharmaceutical portfolio. The Board believes that a divisionAlready a subscriber Login You have read all your…
